Showing 9,481 - 9,500 results of 45,491 for search '(( 5 ((ng decrease) OR (mean decrease)) ) OR ( 50 ((we decrease) OR (a decrease)) ))', query time: 1.36s Refine Results
  1. 9481
  2. 9482
  3. 9483
  4. 9484

    Requirement of NF-κB activation for cytokine-mediated reductions in TEER. by Paul R. Clark (714064)

    Published 2015
    “…Conditions are lane 1, DMSO Control; lanes, 2, 3, 4 and 5, Bay11 at 0.375, 0.75, 1.5 and 3.0 μM, respectively all after 0.8 ng/ml TNF for 16 hours. …”
  5. 9485

    Glycochenodexycholic (GCDCA) causes lumen obstruction and subepithelial fibrosis of neonatal extrahepatic bile ducts (EHBDs), while ursodeoxycholic acid (UDCA) attenuates GCDCA tox... by Miri Dotan (12250909)

    Published 2022
    “…<p>(a) Neonatal EHBD were dissected and incubated for 24 hours in biliary epithelial cell media, with or without GCDCA 5mM, and with GCDCA 5mM combined with UDCA acid 5mM. …”
  6. 9486
  7. 9487
  8. 9488
  9. 9489

    Csf1r or Mer inhibition delays liver regeneration via suppression of Kupffer cells by Juan A. Santamaria-Barria (6655667)

    Published 2019
    “…At 36h after PH, Csf1r inhibition increased serum ALT and histological liver injury, and decreased liver cell proliferation. A small molecule inhibitor of Mer did not alter the percentage of KCs or their proliferation and just modestly delayed LR. …”
  10. 9490
  11. 9491
  12. 9492
  13. 9493
  14. 9494
  15. 9495
  16. 9496
  17. 9497
  18. 9498
  19. 9499
  20. 9500

    Effects of AP-5 application on EPSCs in control and hyperglycemic mice. by Eva C. Bach (709723)

    Published 2015
    “…<b>D.</b> Mean percent decrease in mEPSC frequency following application of AP-5 in control (n = 9) and hyperglycemic (n = 10) mice. …”